ECSP20029558A - Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb) - Google Patents
Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)Info
- Publication number
- ECSP20029558A ECSP20029558A ECSENADI202029558A ECDI202029558A ECSP20029558A EC SP20029558 A ECSP20029558 A EC SP20029558A EC SENADI202029558 A ECSENADI202029558 A EC SENADI202029558A EC DI202029558 A ECDI202029558 A EC DI202029558A EC SP20029558 A ECSP20029558 A EC SP20029558A
- Authority
- EC
- Ecuador
- Prior art keywords
- hbv
- virus
- thiazol
- amino
- high activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere, en general, a nuevos agentes antivirales. Específicamente, la presente invención se refiere a compuestos que pueden inhibir la proteína o proteínas codificada(s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, a composiciones que comprenden estos compuestos, a métodos para inhibir la replicación del virus VHB, a métodos para tratar o prevenir la infección por VHB y a procesos o intermedios para fabricar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199687 | 2017-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20029558A true ECSP20029558A (es) | 2020-07-31 |
Family
ID=60201941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202029558A ECSP20029558A (es) | 2017-11-02 | 2020-06-01 | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11267825B2 (es) |
| EP (1) | EP3704127A1 (es) |
| JP (1) | JP2021501764A (es) |
| KR (1) | KR20200083551A (es) |
| CN (1) | CN111448199A (es) |
| AR (1) | AR113826A1 (es) |
| AU (1) | AU2018361364B2 (es) |
| BR (1) | BR112020008762A2 (es) |
| CA (1) | CA3081386A1 (es) |
| CL (1) | CL2020001145A1 (es) |
| CU (1) | CU20200037A7 (es) |
| EA (1) | EA202091113A1 (es) |
| EC (1) | ECSP20029558A (es) |
| GE (1) | GEP20227373B (es) |
| IL (1) | IL274298A (es) |
| MA (1) | MA50524A (es) |
| MX (1) | MX2020004839A (es) |
| PH (1) | PH12020550525A1 (es) |
| SG (1) | SG11202003700TA (es) |
| TW (1) | TW201930315A (es) |
| UY (1) | UY37962A (es) |
| WO (1) | WO2019086141A1 (es) |
| ZA (1) | ZA202002249B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR116947A1 (es) * | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| MX2021013085A (es) * | 2019-04-30 | 2021-11-17 | Aicuris Gmbh & Co Kg | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb). |
| US11976084B2 (en) | 2020-11-23 | 2024-05-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023137007A1 (en) * | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
| CN116068100A (zh) * | 2022-11-24 | 2023-05-05 | 上海研诺医药科技有限公司 | 一种测定4-羟乙基哌嗪乙磺酸的检测方法 |
| CN116396204B (zh) * | 2023-03-29 | 2024-09-24 | 无锡科华生物科技有限公司 | 一种4,6,7-三氟-1h-吲哚-2-羧酸的制备方法 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998040385A1 (en) | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
| WO2001045712A1 (de) | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Arzneimittelkombinationen gegen virale erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| CN101914107B (zh) | 2003-11-12 | 2012-03-07 | 第一三共株式会社 | 噻唑衍生物的制备方法 |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| US7795262B2 (en) | 2006-03-10 | 2010-09-14 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
| UY30867A1 (es) | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos analogos de piridina vii 543 |
| JP5508400B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| US8024013B2 (en) | 2008-07-09 | 2011-09-20 | Sony Ericsson Mobile Communications Ab | Regulating power duty cycle of an RF transmitter/receiver responsive to distance moved |
| US20110230472A1 (en) | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
| JP5651681B2 (ja) | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法 |
| WO2012031024A1 (en) | 2010-08-31 | 2012-03-08 | Vanderbilt University | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors |
| ES2558531T3 (es) | 2010-09-02 | 2016-02-05 | Suven Life Sciences Limited | Compuestos de heterociclilo como ligandos de receptores de histamina H3 |
| US9334256B2 (en) | 2011-06-15 | 2016-05-10 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| EP2776405A1 (en) | 2011-11-11 | 2014-09-17 | Pfizer Inc | 2-thiopyrimidinones |
| EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
| UY34566A (es) | 2012-01-06 | 2013-07-31 | Janssen R & D Ireland | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| PL2890683T3 (pl) | 2012-08-28 | 2017-06-30 | Janssen Sciences Ireland Uc | Pochodne skondensowanego bicyklicznego sulfamylu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| UA123256C2 (uk) | 2012-08-28 | 2021-03-10 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b |
| WO2014113191A1 (en) | 2013-01-15 | 2014-07-24 | Xiaohu Zhang | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
| WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| AU2014267235B2 (en) | 2013-05-17 | 2017-10-05 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9266904B2 (en) | 2013-05-17 | 2016-02-23 | Hoffmann-La Roche Inc. | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| JP6348978B2 (ja) | 2013-07-25 | 2018-06-27 | ヤンセン・サイエンシズ・アイルランド・ユーシー | グリオキサミド置換ピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用 |
| WO2015057945A1 (en) | 2013-10-18 | 2015-04-23 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
| ES2777248T3 (es) | 2013-11-14 | 2020-08-04 | Novira Therapeutics Inc | Derivados de azepano y métodos de tratar infecciones por hepatitis B |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| DK3114128T3 (en) | 2014-03-07 | 2019-03-25 | Hoffmann La Roche | New 6-fused heteroaryld dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| RS59430B1 (sr) | 2014-03-13 | 2019-11-29 | Univ Indiana Res & Tech Corp | Alosterni modulatori proteina jezgra hepatitisa b |
| MX2016012573A (es) | 2014-03-28 | 2018-02-19 | Sunshine Lake Pharma Co Ltd | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. |
| WO2015172128A1 (en) | 2014-05-09 | 2015-11-12 | Indiana University Research And Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| EP3180319B1 (en) | 2014-08-14 | 2018-10-03 | F.Hoffmann-La Roche Ag | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection |
| CA2969557A1 (en) | 2014-12-02 | 2016-06-09 | Novira Therapeutics, Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment |
| US9518057B2 (en) | 2014-12-30 | 2016-12-13 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| KR20170113658A (ko) | 2015-03-16 | 2017-10-12 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료 |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| JP6462155B2 (ja) | 2015-05-04 | 2019-01-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017013046A1 (en) | 2015-07-21 | 2017-01-26 | F. Hoffmann-La Roche Ag | Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TWI721016B (zh) | 2015-09-15 | 2021-03-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
| JP6523566B2 (ja) | 2015-11-04 | 2019-06-05 | チールー ファーマシューティカル カンパニー、リミテッド | ジヒドロピリド環化合物の結晶形、製造方法および中間体 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| EP3458455B1 (en) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| JP7034133B2 (ja) | 2016-07-14 | 2022-03-11 | エフ．ホフマン－ラ ロシュ アーゲー | 感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物 |
| WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011163A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CA3036245C (en) | 2016-09-13 | 2021-07-20 | Arbutus Biopharma Corporation | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| KR20190126102A (ko) | 2017-03-02 | 2019-11-08 | 어셈블리 바이오사이언시스, 인크. | 시클릭 술파미드 화합물 및 그의 사용 방법 |
| SG11201908569QA (en) | 2017-03-21 | 2019-10-30 | Arbutus Biopharma Corp | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| SG11202003746UA (en) * | 2017-11-02 | 2020-05-28 | Aicuris Gmbh & Co Kg | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
-
2018
- 2018-11-02 EP EP18811439.1A patent/EP3704127A1/en not_active Withdrawn
- 2018-11-02 GE GEAP201815351A patent/GEP20227373B/en unknown
- 2018-11-02 AR ARP180103202A patent/AR113826A1/es unknown
- 2018-11-02 AU AU2018361364A patent/AU2018361364B2/en not_active Ceased
- 2018-11-02 US US16/761,189 patent/US11267825B2/en active Active
- 2018-11-02 CA CA3081386A patent/CA3081386A1/en not_active Abandoned
- 2018-11-02 EA EA202091113A patent/EA202091113A1/ru unknown
- 2018-11-02 CN CN201880079554.1A patent/CN111448199A/zh active Pending
- 2018-11-02 MA MA050524A patent/MA50524A/fr unknown
- 2018-11-02 CU CU2020000037A patent/CU20200037A7/es unknown
- 2018-11-02 BR BR112020008762-9A patent/BR112020008762A2/pt not_active IP Right Cessation
- 2018-11-02 JP JP2020524457A patent/JP2021501764A/ja active Pending
- 2018-11-02 TW TW107139067A patent/TW201930315A/zh unknown
- 2018-11-02 MX MX2020004839A patent/MX2020004839A/es unknown
- 2018-11-02 KR KR1020207015662A patent/KR20200083551A/ko not_active Application Discontinuation
- 2018-11-02 SG SG11202003700TA patent/SG11202003700TA/en unknown
- 2018-11-02 WO PCT/EP2018/000502 patent/WO2019086141A1/en active Application Filing
- 2018-11-05 UY UY0001037962A patent/UY37962A/es not_active Application Discontinuation
-
2020
- 2020-04-27 IL IL274298A patent/IL274298A/en unknown
- 2020-04-30 CL CL2020001145A patent/CL2020001145A1/es unknown
- 2020-04-30 PH PH12020550525A patent/PH12020550525A1/en unknown
- 2020-05-04 ZA ZA2020/02249A patent/ZA202002249B/en unknown
- 2020-06-01 EC ECSENADI202029558A patent/ECSP20029558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020004839A (es) | 2020-10-16 |
| KR20200083551A (ko) | 2020-07-08 |
| US20200354379A1 (en) | 2020-11-12 |
| AU2018361364A1 (en) | 2020-05-21 |
| ZA202002249B (en) | 2022-01-26 |
| BR112020008762A2 (pt) | 2020-10-20 |
| CL2020001145A1 (es) | 2020-10-09 |
| GEP20227373B (en) | 2022-04-25 |
| SG11202003700TA (en) | 2020-05-28 |
| JP2021501764A (ja) | 2021-01-21 |
| US11267825B2 (en) | 2022-03-08 |
| WO2019086141A1 (en) | 2019-05-09 |
| UY37962A (es) | 2019-05-31 |
| PH12020550525A1 (en) | 2021-04-26 |
| CU20200037A7 (es) | 2021-03-11 |
| EA202091113A1 (ru) | 2020-08-28 |
| IL274298A (en) | 2020-06-30 |
| CA3081386A1 (en) | 2019-05-09 |
| AR113826A1 (es) | 2020-06-17 |
| EP3704127A1 (en) | 2020-09-09 |
| TW201930315A (zh) | 2019-08-01 |
| WO2019086141A8 (en) | 2019-08-29 |
| CN111448199A (zh) | 2020-07-24 |
| MA50524A (fr) | 2020-09-09 |
| AU2018361364B2 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20029569A (es) | Nuevas indol-2-carboxamidas sustituidas con pirazolo piperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb) | |
| ECSP20029558A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb) | |
| UY38434A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) | |
| CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
| CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
| CL2018002528A1 (es) | Agentes anti virales de la hepatitis b. | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| ECSP21031082A (es) | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) | |
| UY38436A (es) | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| ECSP21079317A (es) | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| ECSP21078893A (es) | Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) | |
| UY38435A (es) | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) | |
| ECSP21080338A (es) | Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb) | |
| UY38439A (es) | Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) | |
| UY38681A (es) | Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| EA202192969A1 (ru) | Новые оксалилпиперазины, активные против вируса гепатита b (вгв) | |
| EA202192967A1 (ru) | Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв) | |
| AR111017A1 (es) | Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c |